Historical analysis of insider trading risks in predictive markets

The article reviews the 2000s ImClone insider trading scandal involving CEO Sam Waksal to illustrate the persistent risks of information asymmetry in financial markets. It highlights how regulatory decisions, such as FDA drug rejections, create high-stakes environments for illicit trading, serving as a cautionary framework for modern predictive market integrity.